Clinical Trials
41 trialsNCT05613088 2026-04-30
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT03519178 2025-11-14
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2 Terminated
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT03522246 2025-06-24
ATHENA
pharmaand GmbH
Phase 3 Active not recruiting
NCT01309230 2025-06-08
A Trial of FANGâ„¢ Vaccine for Participants With Ovarian Cancer
Gradalis, Inc.
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT04493619 2024-11-04
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
Phase 1/2 Terminated
NCT04296890 2024-08-07
SORAYA
ImmunoGen, Inc.
Phase 3 Completed
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT04676334 2024-05-07
CATCH-R
pharmaand GmbH
Phase 3 Completed
NCT04148937 2024-04-05
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02915523 2024-01-10
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT01891344 2023-06-12
ARIEL2
pharmaand GmbH
Phase 2 Completed
NCT03824704 2023-06-12
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Phase 2 Terminated
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT02762981 2022-12-06
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
Phase 1/2 Completed
NCT03106987 2022-10-07
OReO
AstraZeneca
Phase 3 Completed
NCT01018563 2021-12-08
An Open Label Extension Study of the Efficacy of MORAb-003
Morphotek
Phase 2 Terminated
NCT01551745 2021-10-19
Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab
Gradalis, Inc.
Phase 2 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT01666444 2019-09-26
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Celgene
Phase 2 Completed
NCT01663857 2019-09-11
A Study LY2228820 for Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed
NCT00326885 2018-10-17
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Neovii Biotech
Phase 2 Completed
NCT00281632 2018-09-17
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01617629 2017-12-08
CAN-003X
Prima BioMed Ltd
Phase 2 Completed
NCT00408603 2017-07-27
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Sunesis Pharmaceuticals
Phase 2 Completed
NCT01068509 2017-05-11
Ovarian Cancer Vaccine for Patients in Remission
Prima BioMed Ltd
Phase 2 Completed
NCT01521143 2016-12-14
CANVAS
Prima BioMed Ltd
Phase 2 Terminated
NCT01447706 2016-05-12
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Merrimack Pharmaceuticals
Phase 2 Completed
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00421889 2015-07-28
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Phase 1/2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00617773 2013-11-26
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Recepta Biopharma
Phase 2 Completed
NCT00377429 2012-07-19
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Neovii Biotech
Phase 2 Completed
NCT00561795 2012-03-22
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
GlaxoSmithKline
Phase 2 Completed